Reference | Dose scheme | Total dose (Gy) | Dose prescr. | Treatment outcome | TCP for LQ (USC) | ||
---|---|---|---|---|---|---|---|
Overall survival | Local control | No LOC | LOC | ||||
Hof et al. 2007[3] (Germany) | 26 Gy × 1 | 26 | Isocenter | 74.5% at 1 yeara, 65.4% at 2 yearsa, 37.4% at 3 yearsa | 100% at 1 yearb, 72% at ≥ 2 yearsb | 0% (0%) | N/A |
Fritz et al. 2008[4] (Germany) | 30 Gy × 1 | 30 | Isocenter | 66% at 2 years, 53% at 3 years | 81% at 3 years | 0% (0%) | N/A |
Zimmermann et al. 2005[5](Germany 65% isodose) | 12.5 Gy × 3 | 37.5 | 60% | 80% at 1 yearc, 75% at 2 yearsc | 100% at 1 yearc, 87% at 2 yearsc | 7% (4%) | 99% (98%) |
Baumann et al. 2009[6] (Sweden) | 15 Gy × 3 | 45 | 67% | 86% at 1 year, 65% at 2 years, 60% at 3 years | 92% at 3 years | 56% (44%) | 100% (99%) |
Olsen et al. 2011[7] (USA, The Netherlands) | 18 Gy × 3 | 54 | 80% | 92/81% at 1 yeard, 85/61% at 2 yearsd | 99% at 1 yeard, 91% at 2 yearsd | 62% (50%) | 100% (100%) |
Haasbeek et al. 2010[8] (The Netherlands) | 20 Gy × 3 | 60 | 80% | 85.7% at 1 yeare, 54% at 2 yearse, 45.1% at 3 yearse | 89% at 3 yearse | 96% (92%) | 100% (100%) |
Takeda et al. 2009[9] (Canada) | 10 Gy × 5 | 50 | 80% | 90/63% at 3 years, (Stage 1A/1B) | 93/96% at 3 years, (Stage 1A/1B) | 0% (0%) | 98% (98%) |
Haasbeek et al. 2010[8] (The Netherlands) | 12 Gy × 5 | 60 | 80% | 85.7% at 1 yeare, 54% at 2 yearse, 45.1% at 3 yearse | 89% at 3 yearse | 29% (28%) | 100% (100%) |
Haasbeek et al. 2010[8] (The Netherlands) | 7.5 Gy × 8 | 60 | 80% | 85.7% at 1 yeare, 54% at 2 yearse, 45.1% at 3 yearse | 89% at 3 yearse | 0% (0%) | 100% (100%) |